Adenocarcinoma, Clear Cell
-
Subject Areas on Research
-
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.
-
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
-
Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer.
-
Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
-
Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer.
-
Adverse health outcomes in women exposed in utero to diethylstilbestrol.
-
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
-
Analgesic medication use and risk of epithelial ovarian cancer in African American women.
-
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
-
Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.
-
Cabozantinib in ovarian clear cell cancers: UnMET expectations.
-
Cancer risk in women exposed to diethylstilbestrol in utero.
-
Clear cell adenocarcinoma in a female urethral diverticulum.
-
Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile.
-
Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.
-
Common variants at 19p13 are associated with susceptibility to ovarian cancer.
-
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
-
Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
-
Epigenetic determinants of ovarian clear cell carcinoma biology.
-
Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.
-
Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma.
-
High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
-
Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.
-
Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
-
Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk.
-
Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
-
Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
-
Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types.
-
Mitochondrial Superoxide Dismutase Has a Protumorigenic Role in Ovarian Clear Cell Carcinoma.
-
Molecular genetics and histopathologic features of adult distal nephron tumors.
-
Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data.
-
Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer.
-
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
-
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
-
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
-
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
-
Predicting occult multifocality of renal cell carcinoma.
-
Prenatal diethylstilbestrol exposure and cancer risk in women.
-
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
-
Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients.
-
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.
-
Risk factors for ovarian cancers with and without microsatellite instability.
-
Risk factors for ovarian cancers with and without microsatellite instability.
-
Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics.
-
Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations.
-
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.
-
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
-
The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
-
The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance.
-
The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
-
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
-
Keywords of People
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
Halabi, Susan,
Professor of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics
-
Moorman, Patricia Gripka,
Professor Emeritus in Family Medicine and Community Health,
Duke Cancer Institute
-
Yan, Hai,
Adjunct Professor of Pathology,
Pathology